Methotrexate
NDC Package 55390-034-10
Package Information
Methotrexate is used to treat certain types of cancer or to control severe psoriasis or rheumatoid arthritis that has not responded to other treatments. Marketed by Bedford Laboratories, this product is identified by NDC 55390-034 and is authorized under FDA application ANDA089343.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 55390 - Bedford Laboratories
- 55390-034 - Methotrexate
- 55390-034-10 - 10 VIAL in 1 BOX, UNIT-DOSE / 10 mL in 1 VIAL
- 55390-034 - Methotrexate
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 55390-034-10 identifies a specific commercial package of 10 vial in 1 box, unit-dose / 10 ml in 1 vial of Methotrexate, labeled by Bedford Laboratories. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Bedford Laboratories on May 01, 1996. The current certification is valid through October 31, 2012.
What are the primary indications for this medication?
Methotrexate is used to treat certain types of cancer or to control severe psoriasis or rheumatoid arthritis that has not responded to other treatments. It may also be used to control juvenile rheumatoid arthritis. Methotrexate belongs to a class of drugs known as antimetabolites. It works by slowing or stopping the growth of cancer cells and suppressing the immune system. Early treatment of rheumatoid arthritis with more aggressive therapy such as methotrexate helps to reduce further joint damage and to preserve joint function.
How is this Bedford Laboratories product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 55390003410. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.